

VEGF R3/FLT4

Catalog # PVGS1817

Product Information

Primary Accession Species	P35916-1 Human
Sequence	Tyr25-Ile776
Purity	> 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
Endotoxin Level	Less than 1EU per μ g by the LAL method.
Biological Activity	Immobilized VEGF-C, His Tag at 1 μ g/ml (100 μ l/Well) on the plate can bind VEGF R3/FLT4 hFc Chimera, Human (Cat.No.: Z03968)
Expression System	HEK293
Theoretical Molecular Weight	111.3 kDa
Formulation	Lyophilized from a 0.22 μ m filtered solution in 50mM Tris, 150mM NaCl, 100mM Glycine (pH 7.5).
Reconstitution	It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH ₂ O more than 100 μ g/ml.
Storage & Stability	Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Additional Information

Target Background	Vascular endothelial growth factor receptor 3 (VEGFR3) is one kind of tyrosine-protein kinase. VEGFR3 acts as a cell-surface receptor for VEGFC and VEGFD. It is a key regulator of lymphatic system development and establishment. VEGFR3 plays important roles in angiogenesis. It is also up-regulated in the endothelium of blood vessels in breast cancer and various other tumors.
--------------------------	--

Protein Information

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.